GeneDx (NASDAQ: WGS) net income
GeneDx reported a net loss of $21.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $52.3m. Earnings per share were −$0.73.
Fiscal 2025 is the highest of the 6 fiscal years on record for GeneDx. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$21.0m | — | −4.9% | −$0.73 |
| 2024 | −$52.3m | — | −17.1% | −$1.94 |
| 2023 | −$175.8m | — | −86.8% | −$7.23 |
| 2022 | −$549.0m | — | −233.9% | −$1.63 |
| 2021 | −$245.4m | — | −115.6% | −$2.27 |
| 2020 | −$241.3m | — | −134.6% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
GeneDx net income compared with its sector
By net income for its latest fiscal year, GeneDx ranks 210th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of GeneDx, −4.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 208th | Heron Therapeutics | −$20.2m | −13.0% |
| 209th | Whitehawk Therapeutics | −$20.6m | −288.3% |
| 210th | GeneDx | −$21.0m | −4.9% |
| 211th | CareDx | −$21.4m | −5.6% |
| 212th | Neuropace | −$21.5m | −21.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of GeneDx
- How much did GeneDx earn in fiscal 2025?
- GeneDx reported a net loss of $21.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $52.3m.
- What are the earnings per share of GeneDx?
- They were −$0.73 in fiscal 2025, compared with −$1.94 in fiscal 2024.
- Where does GeneDx rank in its sector by net income?
- It ranks 210th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for GeneDx come from?
- From the annual report (Form 10-K) that GeneDx files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that GeneDx files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on GeneDx: the GeneDx page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.